|
NIH completes Nanomedicine Network
The
National Institutes of Health (NIH) has completed its
national network of eight Nanomedicine Development Centers
(NDCs). They are: Baylor College of Medicine in Houston;
Columbia University, New York Morningside; Georgia Institute
of Technology in Atlanta; Purdue University in Lafayette,
Indiana; University of California at Los Angeles; University
of California Lawrence Berkeley National Laboratory;
University of Illinois Urbana-Champaign; University
of California at San Francisco.
NDCs are staffed by multidisciplinary scientific teams,
including biologists, physicians, chemists, physicists,
mathematicians, engineers, and computer scientists.
In addition to conducting research into the physical
properties of structures inside cells to determine how
biology’s molecular machines are built, these
teams will begin training the next generation of students
in this emerging field of medical science. The Nanomedicine
Initiative applies an engineering approach to the study
of cellular and subcellular systems in an effort not
only to understand, but to precisely control molecular
complexes that operate at the nanoscale. This will allow
for development of new technologies to prevent or cure
disease and to repair damaged tissue.
The Nanomedicine Initiative, part of NIH’s Roadmap
for Medical Research, is led by Paul A. Sieving, M.D.,
Ph.D., director of the National Eye Institute (NEI),
Jeffery Schloss, Ph.D., program director, Technology
Development, National Human Genome Research Institute,
and Richard S. Fisher, Ph.D., program director, Corneal
Diseases at NEI, in collaboration with a program team
representing institutes and centers across the NIH.
“Future progress in medicine will depend on our
understanding and modulating the complexity of biological
systems,” said Dr. Sieving. “The NIH Roadmap,
including the Nanomedicine Initiative, will advance
our knowledge of biological systems. This will provide
the scientific foundation for new strategies for diagnosing,
treating, and preventing disease.”
Visit: http://nihroadmap.nih.gov/nanomedicine/index.asp
 |
